Report Detail
U.S. Markets for Invasive and Noninvasive Diagnostic Cardiology Products, October 2014
In the next decade, the number of people living in the United States (U.S.) with diseases/disorders of the heart and vascular system is expected to continue to increase along with expansion in the elderly segment of the population and growth in the number of people with chronic conditions such as cardiovascular disease (CVD), diabetes, and obesity, which are exacerbated by unhealthful behaviors such as physical inactivity and tobacco smoking.
Diagnostic interventional cardiology procedures covered by the scope of this report include electrocardiography (ECG); non-invasive imaging systems including computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine, ultrasound, and X-ray; invasive diagnostic imaging systems including standard transcatheter coronary and peripheral angiography, electrophyiosology (EP) products, guidewire-based intravascular stenosis assessment, intracardiac echocardiography (ICE), intravascular ultrasound (IVUS), and optical coherence tomography (OCT); and in vitro diagnostics systems including cardiac markers, cholesterol testing products, and point-of-care/home coagulation monitoring systems. In the U.S. it is expected that the combined volume of these procedures will grow at a compound annual rate of 1.4% over the next half-decade, increasing from approximately 5.5 million in 2013 to an estimated 5.9 million in the year 2018. The total product sales for invasive and noninvasive diagnostic cardiology systems is expected to grow at a compound annual rate of 3.4% over the forecast period covered by this report, from approximately $3.8 billion in 2013 to an estimated $4.4 billion in the year 2018.